Background: Growth failure is well-recognized in pediatric inflammatory bowel disease (PIBD; <18 years). We aimed to examine whether antitumor necrosis factor (TNF) therapy improves growth in a PIBD population-based cohort. Conclusions: Anti-TNF therapy is more likely to be associated with growth improvement when used at earlier stages of puberty with remission a key growth-promoting strategy in pediatric Crohn disease.
T he treatment of pediatric inflammatory bowel disease (PIBD) has evolved significantly in recent years with the advent of antitumor necrosis factor (TNF) therapy reducing inflammation, improving mucosal healing, and reducing disease relapse/corticosteroid usage; however, finding a therapy that can improve long-term linear growth has proven more elusive (1) (2) (3) . The presence of poor
What Is Known
Growth is adversely affected in active inflammatory bowel disease especially Crohn disease. Infliximab and adalimumab are associated with improvement in short-term growth with most studies being single center and non-population based.
What Is New
Children who are treated with infliximab for ! 12 months, achieve remission after induction, and are in the early stages of puberty demonstrate improved linear growth. Children with disease duration at the start of infliximab of !2 years demonstrated improved linear growth compared to those with disease for 2 years. Combination therapy with infliximab and azathioprine results in greater improvement in linear growth.
growth and short stature in PIBD, and more specifically, Crohn disease (CD) has been described for some time; this can lead to a significant effect on final adult height with varying reports of 20% to 30% of children with CD having a reduced adult height (4) . The potential reasons for this negative effect on growth are likely to be multifactorial and include malabsorption, decreased oral intake, uncontrolled inflammation, increased requirements, and losses of energy and nutrients; this can often be exacerbated by impaired growth, which can precede clinical symptoms in 42% of children (5) . Further research into the mechanisms surrounding growth failure have shown a modulatory role of proinflammatory cytokines such as tumor necrosis factor-alpha (TNFa) and interleukins (IL) and a degree of growth hormone resistance (6, 7) .
As anti-TNF therapy usage has increased, the evidence on the long-term efficacy has improved (8) . Despite further evidence and better understanding, many issues have yet to be resolved including identifying patients likely to have a prolonged treatment response and then balancing the risk/benefit of combination therapy with anti-TNF and immunomodulator (IM) versus monotherapy with anti-TNF therapy alone. The 2 most commonly used anti-TNF agents in PIBD are infliximab (IFX) and adalimumab (ADA). Both have been shown to be effective in the induction and maintenance of remission for pediatric CD and similarly for IFX in ulcerative colitis (UC) (1, (9) (10) (11) . The evidence on the efficacy of IFX on short-term growth is generally supportive with several studies showing clear benefit (12) (13) (14) (15) (16) ; however, other published studies have shown no beneficial effect (17) (18) (19) (20) . A recent systematic review on pediatric anti-TNF therapy concluded that IFX did have a positive effect on growth in CD, particularly in pre-or early puberty but did not mention growth outcomes of those treated with ADA (21) . Fewer growth data exist on ADA, but ADA does also demonstrate an improvement in short-term (22) and long-term growth (10) more pronounced in those who enter remission (23) .
The aim of the present study was to characterize growth in a population-based cohort of children with all types of IBD, treated with ADA and/or IFX between 2000 and 2012 in Scotland, using data from the Scottish PIBD biological registry.
METHODS
Data were gathered from the 3 regional Pediatric Gastroenterology, Hepatology and Nutrition (PGHAN) shared care networks (West, South-East, and North of Scotland) involving all 3 tertiary PGHAN centers (Glasgow, Edinburgh, and Aberdeen) and all pediatric units in district general hospitals, which form a Scottish PGHAN managed service network, covering all patients with PIBD in pediatric services.
Case Identification
All patients with PIBD within pediatric services were included in the Scottish Pediatric biological registry if younger than 18 years at the start of biological therapy, from January 1, 2000 to December 31, 2012 with a minimum follow-up of 10 weeks, as previously described (24) . Patients were included who had growth data available for a minimum of 24 months; 12 months before commencing anti-TNF therapy and for 12 months after treatment commenced, if further growth data were available this was also captured. Data on some of the patients within the present study have been included in previous related publications (2, 11, 23) . Patients were given IFX for fistulating CD outside of the licensed indications. One patient was excluded as was receiving recombinant human growth hormone as growth promoting treatment. Drug administration and dose adjustment were given as previously described (24) .
Data Collection
Data were collected as previously described on demographics including disease phenotype as per the Montreal criteria (25) ; biological schedule and regimen (induction only; induction then maintenance); medications (including corticosteroids, thiopurines, and methotrexate [MTX]); and surgery before, at, and after biological start (24) . Disease activity was assessed by physician global assessment (PGA) through history, clinical examination, anthropometry, and laboratory values by the clinician and divided into quiescent (remission), mild, and moderate/severe. A treatment course was defined as the duration of each anti-TNF agent the patient received.
Data were collected until study end on March 31, 2013 unless prior transition to adult services or emigration from Scotland. Height and weight data were collected for IFX during 48 months for all PIBD subtypes (CD, UC, inflammatory bowel disease unclassified) at the following time points: 12 months before commencing IFX (T-12), at start of IFX (T0), 12 (Tþ12), 24 (Tþ24), and 36 (Tþ36) months post-IFX start). Because of transition and variable length of follow-up for each patient, a smaller cohort had growth data available for 24 and 36 months after start of IFX (Fig. 1 Height was measured using wall-mounted stadiometers according to Frankfurt plane position and weight measured wearing minimal clothing using calibrated seat scales to the nearest 100 g. These data were converted to standard deviation scores for height (Ht SDS), weight (Wt SDS), and body mass index (BMI) (BMI SDS) using 1990 British childhood standards (26, 27) , then D height SDS (DHt SDS) and height velocity (HV) were calculated for T0 and Tþ12. Delta Ht SDS at T0 was calculated by subtracting the Ht SDS at T0 from Ht SDS at T-12, for DHt SDS at Tþ12 then Ht SDS at T12 was subtracted from Ht SDS at T0. Pubertal staging was assessed using either a validated self-assessment form or by clinical examination (28, 29) and was documented at baseline, 12, 24, and 36 months where available.
Ethical approval is not required in NHS Scotland for retrospective case record reviews with examination of departmental databases of service design/delivery, such as in PISA (the Pediatric-onset IBD Scottish Audit), comprising epidemiology (30) , and the Scottish PIBD biological registry (24) .
Statistical Analysis
Descriptive statistics are presented as median with 90th percentiles. Wilcoxon was used to examine differences in height, weight, and BMI SDS. A standard significance level of 0.012 was adopted due to multiple comparison testing and was calculated using a Bonferroni correction. Analyses were carried out using SPSS (IBM 19, Chicago, IL) IBM. Multiple logistic regression was performed using R v3.0.2 (R Foundation for Statistical Computing, Vienna, Austria) and all patients with satisfactory growth data were combined. Confounders including type of IBD, small bowel involvement, azathioprine (AZA) use, MTX use, duration of disease, Tanner pubertal staging, remission, corticosteroid use at baseline, PGA at baseline, Ht SDS at baseline, and whether patients received maintenance therapy with anti-TNF were entered into the model. There was a degree of duplication in the data as certain patients received both IFX and ADA so for those patients, one of the treatment periods was randomly excluded to ensure a robust model with no autocorrelation. A general linear model was used; a correction was performed to minimize the effect of missing Tanner staging data using the adjusted general linear model.
RESULTS

General Characteristics
One hundred ninety-five patients were included in the initial cohort who were treated with 240 courses of therapy with a biologic, 164 (85%) had CD, 28 (14%) had UC, and 3 had (1%) inflammatory bowel disease unclassified. Most, 115 (60%), were boys with a median age of 11.2 years (range 2.7-17.2) at diagnosis. One hundred ninety-one received IFX and 49 received ADA (4 received ADA alone).
Infliximab Cohort
Satisfactory 24-month growth data were available for 93 of 191 (49%) (Fig. 1) ; 57 (61%) were boys and 86 (92%) had CD with 7 (8%) having UC. Median age at diagnosis was 10.4 years (range 2.7-15.2) and median age at the start of IFX was 13.8 years (range 5.9-17.6). In the 93 in whom satisfactory growth data were available for 24 months, the most common disease location in CD was panenteric in 28 (33%) children with inflammatory the most common behavior in 76 (88%), whereas 86% had extensive UC. The commonest indication for starting IFX was active luminal disease followed by IM failure in CD, whereas for UC it was chronic active colitis followed again by IM failure (Table 1) . At the start of the treatment 18% had Ht SDS <À2, improving only to 15% then 7% at 1 year and 2 years, respectively after treatment with IFX (P > 0.05). Forty-one patients underwent surgery (18 pre-IFX); all of whom had CD. Most patients had disease for >2 years (n ¼ 62) having a median duration of 3.5 years before starting IFX, whereas those <2 years (n ¼ 31) had their disease for 1.3 years. Pubertal data were available in 65 of 93.
Sixty-six patients received further IFX after induction, including 6 patients who received episodic dosing before 2007, with 42 subsequently discontinuing maintenance IFX after a median of 1.0 years (range 0.2-3.2) receiving a median of 8 doses (range 1-25) (Fig. 1) . The most common reasons for discontinuation of those on maintenance IFX were loss of response in 15, planned drug withdrawal in 13, primary nonresponse in 8, an allergic reaction in 5, and an adverse event in 1. Thirty (45%), all with CD, required dose escalation, most commonly increased frequency in 23 (77%), whereas 22 (73%) had an increased dose.
In the 93 children with satisfactory 24-month growth data, median Ht SDS at T-12 was À0.7 (À2.2, À0.7), worsened to median Ht SDS À0.8 (À2.5,À0.5) at T0, and remained similar with a median Ht SDS À0.8 (À2.3,0.7) at Tþ12 (P < 0.001). Median DHt SDS was À0.2 (À0.6, 0.3) at T0 and increased to a median DHt SDS at Tþ12 of 0.1 (À0.4, 0.6) (P < 0.001). Median HV at T0 was 3.5 (1.0, 7.2) cm/year and which increased to 4.4 (1.2, 9.1) at T12 (P ¼ 0.003). No further sustained improvement in linear growth was seen beyond 12 months after starting anti-TNF in those who were followed up for 36 months, the extended growth cohort (Table 2) .
Factors Affecting Growth
Achieving remission was associated with a significant improvement in median Ht SDS, D Ht SDS, and HV (Fig. 2) . Early stages of puberty, Tanner stages 1-3, were associated with an increase in D Ht SDS and HV (Fig. 3 ). Twenty-two of 94 were Tanner stage 4-5 and showed no significant change in Ht SDS and DHt SDS and a decrease in HV; Ht SDS at T0 À0.2 (À1.8, 1.1) to À0.3 (À2.0, 1.1) at Tþ12 (P ¼ 0.78), DHt SDS at Tþ0 À0.14 (À0.5, 0.9) then D Ht SDS at Tþ12 À0.01 (À0.5, 0.9) (P ¼ 0.78) and HV at T0 3.5 (1.0, 9.8) decreased to 2.1 (0.2, 4.4) at Tþ12 (P ¼ 0.001). Sixty (65%) of those treated with IFX had a disease duration ! 2 years at the start of their treatment with IFX and had increased Ht SDS, DHt SDS, and HV at Tþ12 compared with those with disease duration 2 years (Table 3) . Boys growth improved compared with girls, with boys DHt SDS and HV increasing significantly, whereas in girls only DHt SDS increased (Table 3 ). In those with moderate disease, improvement was noted in DHt SDS and HV (Table 3) . Eighty-two (88%) were on IMs at baseline and an increase in Ht SDS, DHt SDS, and HV at Tþ12 was noted in this cohort compared with no improvement in those not on IM. Further analysis was performed on type of IM, given that 42 patients were on AZA and 40 on MTX; there was no significant difference between the AZA and MTX groups in DHt SDS at Tþ12 (P ¼ 0.64, 95% confidence interval À0.2, 0.1). AZA usage was associated with increased Ht SDS, DHt SDS, and HV compared with only improvement in DHt SDS and HV in those on MTX (Table 3) .
Patients who received induction and maintenance (n ¼ 66 [I&M]) showed improvement in Ht SDS, DHt SDS, and HV compared with those who received induction only in whom only D Ht SDS increased (n ¼ 37 [I only]). Patients who were established on maintenance IFX for ! 12 months from first induction dose had significantly increased DHt SDS and HV (Table 3) . Corticosteroid use at baseline was associated with significant improvement in Ht SDS and DHt SDS (Table 3) . Increase was noted in Ht SDS, DHt SDS, and HV in those who did not have surgery (n ¼ 68), whereas no significant improvement was observed in those who underwent surgery post-IFX (n ¼ 25) (Table 3) . No improvement in Ht was observed in those with UC (data available on request). Results are expressed as median (range) and number (%). ADA ¼ adalimumab; IFX ¼ infliximab; L5 ¼ isolated perianal disease.
General Characteristics for Adalimumab
Satisfactory 24-month growth data were available for 28 patients treated with ADA; 12 were girls, 27 with CD ( Table 1 ) and 18 of whom had IFX growth data analyzed previously. All patients treated with ADA increased DHt SDS at 12 months only (see Supplemental Digital Content, Table 1 , http://links.lww.com/ MPG/A764). Early stages of puberty (Tanner stages 2 and 3) were associated with increased DHt SDS and HV and improvement was seen in DHt SDS in boys only (see Supplemental Digital Content, Table 2 , http://links.lww.com/MPG/A764). No improvement was seen in those who were not on corticosteroids at baseline (n ¼ 16) or those who achieved remission at week 4 (n ¼ 5) (data available on request).
Multiple Regression
Multiple regression models were used to determine associations of therapy and disease on DHt SDS at Tþ12 for both IFX and ADA combined. The following variables were inserted into both models: DHt SDS T0, remission, Tanner staging of puberty, AZA use, MTX use, corticosteroid usage at baseline, type of IBD, PGA at baseline, small bowel involvement, maintenance therapy given, and duration of disease until anti-TNF commenced. In the final model only corticosteroid use at baseline was associated with an improvement in D Ht SDS at 12 months (P ¼ 0.02) (95% confidence interval 0.03, 0.39).
DISCUSSION
In our Scottish population-based cohort of children with all subtypes of PIBD treated with either IFX or ADA, anti-TNF therapy was associated with improved linear growth as has been demonstrated in other population-based cohorts for IFX (31,32) ; however, to our knowledge this is the first population-based ADA study. At induction of IFX, 18% of children had an Ht SDS <À2, improving to 15% then 7% at 1 year and 2 years, respectively after treatment. We have also demonstrated that IFX therapy improved linear growth in those who achieved remission, had disease duration for more than 2 years at anti-TNF start, and were in the early stages puberty (Tanner stage 1-3). In addition, we have also shown that improved DHt SDS at 12 months after start of anti-TNF therapy is associated with corticosteroid use at baseline.
The rates of growth failure seen in our cohort are similar to other population-based cohorts of a similar size. In the largest population-based multicenter inception cohort from Northern France, approximately 10% of all newly diagnosed children with CD had severe growth failure (Ht SDS <À2 SDS), improving only slightly to 8% at 1 year and 6.5% at 2 years (31); however, no pubertal data were provided. At diagnosis, children had a mean Ht SDS of À0.57 AE 1.2 compared with À0.83 AE 1.1 in our cohort. Rates of immunomodulation were similar in both cohorts but the median age at first IFX dose in the French group was 18 years contrasting with 13.2 years in our cohort (given data on PIBD cases in EPIMAD are collected both before and after transition to adult IBD services; time of transition is study end in the Scottish PIBD biological registry); the younger age in our cohort may explain the increase in poor growth because the disease may have presented earlier so having an adverse effect at crucial point in the child's growth. The 2 other nationwide population-based study examining use of IFX showed differing results; firstly De Ridder observed that in 6 patients with CD with Ht SDS < 1 at initiation of IFX, 3 subsequently resumed normal growth velocity who remained on IFX after induction (32). Wewer et al (18) showed that in 10 patients with CD who had IFX in part due to growth failure had no improvement noted in HV when compared before and after treatment (no pubertal data or Ht SDS were provided for this cohort). The effect of pubertal stage on linear growth change in children treated with IFX remains controversial. Initially growth was shown to be dependent on progression through puberty with no improvement seen in those Tanner 4 and 5 compared with Tanner 1-3, although it was noted that those in Tanner 1-3 grew at a suboptimal rate (12) . This was again demonstrated in a larger cohort of newly diagnosed patients in North America who were treated with IFX where greater improvement was seen in those in early puberty; the improvement in growth was hypothesized to be related to pubertal progress after initiation of IFX (17) . This contrasts with the findings of Malik et al (2) who demonstrated improved HV SDS 6 months after IFX even after the analysis was adjusted for pubertal staging. In our study, we observed similar results to Malik with improvement seen in Tanner 1 and in Tanner 2/3 in D Ht SDS and HV but we did not observe an improvement in Ht SDS in either group; this supports the theory that the improvement in growth is not only due to pubertal progression, with similar improvements seen in prepubertal children as those in puberty. A further theory is that IFX merely prevents further deterioration in height without improving overall height (33) . Only half on those who were, however, Tanner stage 1 at start of IFX remained Tanner 1 at 12 months, which may have influenced their growth.
Growth improves with greater disease control as can be seen in our results, where no improvement in growth was observed in those who did not achieve remission after induction. In those who achieved remission postinduction, improvement was seen in all measures of growth suggesting that these patients may demonstrate catch up growth now that the inflammatory process has been ''switched off'' rather than the anti-TNF therapy agents themselves. This has previously been demonstrated in the extension to the REACH study, which followed patients up to 12 months and observed a trend toward continued improvement in Ht SDS in those with sustained remission (34) . Other therapies which have, however, been proven to be highly successful at inducing remission, such as exclusive enteral nutrition, have not shown similar improvements in linear growth potentially due to the relatively short-term effect of this treatment.
An interesting finding of the present study was the associated improvement in linear growth in those receiving corticosteroids at induction, most evidence would suggest that corticosteroid usage is associated with poor growth (35) yet not in this cohort. There are several possibilities for this, one is that these children had received steroids before anti-TNF therapy and with the introduction of these agents corticosteroids were able to be weaned leading to improved growth (17) , another is that corticosteroid usage combined with anti-TNF therapy resulted in these children entering remission earlier consequently resulting in improved growth. The definition of remission used in studies varies; some would define remission only as clinical resolution of symptoms, some combine this with specified disease activity indices (eg, Pediatric Crohn's Disease Activity Index [PCDAI] <10), others include normality of laboratory tests including fecal calprotectin, whereas the current definition of true remission for many now includes mucosal healing in addition to clinical and biochemical improvement (36) . Mucosal healing has been associated with prolonged remission after induction treatment with IFX (37) and could potentially be associated with sustained improvement in linear growth too. Potentially those who improved growth parameters only slightly despite being in clinical remission had not in fact achieved mucosal healing, which may then have continued to adversely affect their height. Further evidence for improved growth after the inflammatory process has been stopped is the improved growth seen in those who continued on IFX for 12 months-these were patients who were more likely to have had a response and it is possible that the IFX in addition to stopping the inflammatory process had an independent role in improving growth. A study which directly correlates the degree of mucosal healing and growth response to biologics would help address whether optimal growth outcomes need so-called ''deep remission.'' In our study, those who had disease for !2 years had improved Ht SDS after 12 months of treatment, D Ht SDS, and HV compared to those with a shorter disease duration of 2 years. This contrasts with most current evidence, which suggests that those with shorter disease duration have a better outcome when treated with anti-TNF; exemplars are the REACH study and ACCENT 1 trial. In the REACH study children had a median duration of disease of 1.6 years before IFX and had an 88% response and 59% remission rate postinduction contrasting with a 66.7% response and 39.1% remission rate in adults in ACCENT 1 trial in which the median duration of disease was 7 years before initiation of IFX (1, 38) . Further evidence is provided by another prospective multicenter North American study that observed improved growth and clinical outcome at 12 months of those treated with early IFX (within 3 months of diagnosis) compared with early IM therapy or no therapy (39) . The reason for improved growth in those with a longer disease course in our cohort could be that the growth and/or pubertal development has been impaired for a prolonged period due to the cytokine-driven inflammatory process but when the inflammation is ''switched off'' with anti-TNF therapy, improved growth is then seen.
In our study, including all subtypes of IBD, we found a significant improvement in linear growth in those treated with combination therapy of AZA and IFX, which contrasts with other studies examining the effect of AZA on growth. The only pediatric RCT on the use of AZA from 2000 observed no significant difference in linear growth between those treated with AZA and placebo at 18 months (40). This was confirmed by Pfefferkorn who found no improvement in height at 12 or 24 months for AZA (17) . A UK study did, however, show improved height with treatment with AZA, but this was not statistically significant. Caution must be observed interpreting the results of this UK study because it was retrospective, before IFX was commonly used and with growth data only available for 44 patients with confounders including concurrent corticosteroid use, disease severity, and pubertal staging data unavailable (41) . Other studies have shown improvement in growth with both MTX monotherapy and used in combination with IFX; in a cohort of 12 patients MTX and IFX combination therapy was effective in improving linear growth (2), whereas MTX monotherapy consistently demonstrates improvement in HV (42) . As yet, there is no mechanism proposed at to potential pathways, which may explain this improvement in growth for either AZA or MTX.
Children who received at least 12 months of therapy with IFX demonstrated improved linear growth compared with those who received induction only or stopped IFX before 12 months. Potential explanations could be that those who continued treatment until 12 months were more likely to achieve remission (only 15% did not achieve remission) thereby having a reduction in inflammation resulting in improvement in linear growth. This theory is supported by evidence from the REACH extension study, which demonstrated an improved trend in those who continued with no disease (n ¼ 11) compared with those with mild/moderate disease (n ¼ 39).
Limited data exist on the effects of ADA on growth and is divided with only 1 randomized control trial, the Imagine trial, which found improvement in HV z scores at 6 and 12 months in both the higher and lower doses of ADA; however, no pubertal data were provided (10) . A multicenter UK and Irish audit demonstrated improved short-term growth and our results are similar to that study demonstrating an improvement in D Ht SDS at 6 months after initiating ADA which continued in our cohort to 12 months; we did not observe the increase in HV previously observed (23) . This UK and Irish study provided crucial pubertal data and showed improved growth in those in Tanner stage 1-3; however, we found no such improvement in those who were prepubertal (Tanner stage 1) but significant improvement in those in Tanner stage 2 and 3 for D Ht SDS and HV suggesting that development through puberty may at least partially explain the improvement in height. No improvement was seen in those in Tanner 4 and 5 as would be expected and been previously shown (23) . Data on lack of effect come from a single-center study from Israel, which found no improvement in height at last follow-up (median of 17.3 months); again no pubertal data were provided (43) . Our results should be interpreted with a degree of caution; this population-based study includes only those treated with anti-TNF therapy, which undoubtedly represents the more severe end of the disease spectrum and where a relatively higher rate of growth failure would be expected. Furthermore, satisfactory growth data were available for only 49% of our cohort of anti-TNF-treated patients and full pubertal status data in 71% of these. As a ''real life'' clinical experience from a nationwide group managed from 3 different centers during a 13-year period there is significant heterogeneity in the data due to changing treatment practices as new evidence emerged and differing rates of uptake of change within these centers; an example of this episodic dosing with IFX in 2000 to 2007 (24) and induction only moving to induction with maintenance given improved outcomes in those that continued (44) . Now treatment algorithms have changed considerably, IFX is given earlier on in treatment course in those patients with a severe phenotype such as those with widespread colonic deep mucosal ulceration, growth failure, or severe perianal disease with episodic treatment abandoned and long-term maintenance being the norm. Other studies have shown the benefit to early aggressive treatment in altering the disease progression (38) , so it is possible that if IFX is given earlier the somewhat modest improvement in growth seen in the present study will become more pronounced.
The results of our large retrospective population-based cohort study shows growth failure is relatively common in the Scottish population who were treated with anti-TNF therapy, with 18% of pediatric patients who subsequently received anti-TNF therapy demonstrating severe growth failure at the start of the therapy. We have demonstrated that IFX and possibly ADA are associated with improved linear growth at 12 months after starting the treatment. In those treated with IFX most improvement is seen in those who achieved remission, had disease for longer than 2 years, received combination therapy with AZA, received maintenance therapy, and were Tanner stages 1-3. For ADA we have shown probable improvement in growth again in those who were Tanner stages 2 and 3. The exact role that anti-TNF therapy plays in improving growth requires further study, including elucidation of more effective treatment strategies to reduce the inflammatory process and promote catch-up growth, so ensuring that young people with IBD can achieve their full growth potential.
